title: Acute lung injury and lung transplantation influence in vitro subtype conversion of pulmonary surfactant.
abstract: The effects of surfactant treatment on surfactant subtype conversion after lung injury were examined. Dogs were subjected to hyperventilation for 8 h with or without surfactant treatment. Lungs were stored for 17 h, and the right lung was transplanted and reperfused for 6 h. Conversion of large aggregate (LA) surfactant to small aggregates was investigated using in vitro surface area cycling. LA from transplanted lungs (Transplant-LA) from the nontreated group converted more rapidly than Transplant-LA from the treated group. Transplant-LA from both groups converted more rapidly than LA from normal lungs. Calculations based on [(3)H]dipalmitoylphosphatidylcholine in the administered surfactant [bovine lipid extract surfactant (BLES)] showed that the endogenous component of Transplant-LA converted more rapidly than the exogenous component. This indicates exogenous BLES did not equilibrate completely with endogenous surfactant. LA from hyperventilated, stored donor right lungs and from the recipients' native lungs from the nontreated group converted more rapidly than corresponding LA in the BLES-treated group. Similar relative conversions were observed with exogenous components from all lungs. Relative conversion of endogenous component from Transplant-LA was more rapid than that from LA from donor's stored right lung or from the recipient's native right lung. Low levels of phenylmethylsulfonyl fluoride inhibited conversion of Transplant-LA to a greater extent than normal LA. LA from all experimental groups had similar protein levels. These studies show acute lung injury, transplant, ischemia-reperfusion, and surfactant treatment have major effects on surfactant subtype integrity.
authors.affiliation: Medical Research Council Group in Fetal and Neonatal Health and Development, Department of Biochemistry and Obstetrics and Gynaecology, University of Western Ontario, London N6A 5A5, Ontario, Canada N6A 4V2.
authors.forename: Gayatri
authors.initials: G
authors.lastname: Maitra
authors.forename: Kevin
authors.initials: K
authors.lastname: Inchley
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Novick
authors.forename: Ruud A W
authors.initials: RA
authors.lastname: Veldhuizen
authors.forename: James F
authors.initials: JF
authors.lastname: Lewis
authors.forename: Fred
authors.initials: F
authors.lastname: Possmayer
mesh_terms: D015060:1,2-Dipalmitoylphosphatidylcholine / Q000378:metabolism; D000208:Acute Disease; D000818:Animals; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006985:Hyperventilation / Q000150:complications; D007511:Ischemia / Q000378:metabolism; D008055:Lipids / Q000494:pharmacology; D008171:Lung Diseases / Q000209:etiology / Q000378:metabolism* / Q000601:surgery*; D016040:Lung Transplantation; D010664:Phenylmethylsulfonyl Fluoride / Q000494:pharmacology; D020033:Protein Isoforms / Q000378:metabolism; D011652:Pulmonary Circulation; D011663:Pulmonary Surfactants / Q000378:metabolism*; D012016:Reference Values
chemical_list: D004791:Enzyme Inhibitors; D008055:Lipids; D020033:Protein Isoforms; D011663:Pulmonary Surfactants; D015060:1,2-Dipalmitoylphosphatidylcholine; D010664:Phenylmethylsulfonyl Fluoride